Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 April 2021
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)Product type:GuidanceProgramme:NICE guidelinePublished: 14 December 2023
Cardiovascular risk assessment and lipid modification (QS100)Product type:Quality standardLast updated: 24 May 2023Published: 4 September 2015
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2016
Familial hypercholesterolaemia (QS41)Product type:Quality standardLast updated: 2 November 2017Published: 13 August 2013
Familial Hypercholesterolaemia genetic screening clinicsProduct type:Shared learningPublished: 31 January 2012
Familial hypercholesterolaemia: identification and management (CG71)Product type:GuidanceProgramme:Clinical guidelineLast updated: 4 October 2019Published: 27 August 2008
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Implementation of a telephone appointment service. Improving access to Familial Hypercholesterolaemia cascade screening.Product type:Shared learningPublished: 18 December 2018
Implementation of NICE TA393/394 in a tertiary Lipid Clinic - the first three years experienceProduct type:Shared learningPublished: 7 October 2019
Improved identification of familial hypercholesterolaemia (FH) in primary careProduct type:Shared learningPublished: 20 March 2015
Improving awareness of Familial Hypercholesterolaemia in primary careProduct type:Shared learningPublished: 24 February 2016
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 October 2021
Innovative Medicines Optimisation Clinic for PCSK9 inhibitors & Statin IntoleranceProduct type:Shared learningPublished: 1 October 2019
Metreleptin for treating lipodystrophy (HST14)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 24 February 2021
New opportunities for the treatment of hyperlipidaemia: Initiation of PCSK9 monoclonal antibodies utilising a multi-disciplinary approach.Product type:Shared learningPublished: 21 March 2019
Re-engineering the Post-Myocardial Infarction Medicines Optimisation PathwayProduct type:Shared learningPublished: 7 February 2018
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) (TA961)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Sebelipase alfa for treating Wolman disease (HST30)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 10 January 2024
Systematic case finding of people with hypertensionProduct type:Shared learningPublished: 5 February 2018